Cargando…

Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study

OBJECTIVE: This phase I study aimed to systematically assess the safety, local tolerability, pharmacokinetics, and preliminary efficacy of topical icotinib hydrochloride cream in patients with mild to moderate plaque psoriasis. MATERIALS AND METHODS: Eligible Chinese adult patients with mild to mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lunfei, Lou, Honggang, Zhou, Jiong, Shen, Ying, Zheng, Min, Ruan, Zourong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521334/
https://www.ncbi.nlm.nih.gov/pubmed/31187048
http://dx.doi.org/10.1155/2019/9072683
_version_ 1783418933618933760
author Liu, Lunfei
Lou, Honggang
Zhou, Jiong
Shen, Ying
Zheng, Min
Ruan, Zourong
author_facet Liu, Lunfei
Lou, Honggang
Zhou, Jiong
Shen, Ying
Zheng, Min
Ruan, Zourong
author_sort Liu, Lunfei
collection PubMed
description OBJECTIVE: This phase I study aimed to systematically assess the safety, local tolerability, pharmacokinetics, and preliminary efficacy of topical icotinib hydrochloride cream in patients with mild to moderate plaque psoriasis. MATERIALS AND METHODS: Eligible Chinese adult patients with mild to moderate psoriasis were assigned to the icotinib cream or vehicle group. Icotinib cream with increasing concentrations (0.5%, 1.0%, 2.0%, and 4.0%) or vehicle were administered by the fingertip unit method to the skin lesions twice a day for 4 weeks. Safety assessments included the incidence and severity of adverse events (AEs), local tolerability at the treatment area, vital signs, and laboratory examinations. Plasma levels of icotinib were also measured for the pharmacokinetics calculation. The efficacy was preliminarily explored by assessing the improvement in the severity level using Target Plaque Severity Score (TPSS) and overall improvement using the Psoriasis Area Severity Index (PASI) and Dermatological Quality Life Index. RESULTS: Forty-one patients were enrolled and qualified for safety analysis. 27 (65.9%) patients experienced at least one AE, of which application-site adverse drug reactions (ADRs) were reported in 6 (14.6%) patients. All ADRs were of grade 1 or 2, most common irritation (4.5%), itching (3.1%), and erythema (2.4%), and resolved during follow-up. The systemic exposure to icotinib was very low; the highest plasma concentration was 0.214 ng/mL, while the area under the curve from 0 to 12 hours was 1.626 h·ng/mL. The TPSS improved for all icotinib groups after treatment in a dose- and time-dependent manner. CONCLUSION: This phase 1 study demonstrated favorable safety, tolerable toxicity, and preliminary efficacy of icotinib cream in patients with mild to moderate psoriasis. The dose concentration of 2.0% (twice daily based on the fingertip unit method) is recommended for further study. STUDY DESIGN: This is a single-center, randomized, double-blind, and vehicle-controlled study.
format Online
Article
Text
id pubmed-6521334
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65213342019-06-11 Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study Liu, Lunfei Lou, Honggang Zhou, Jiong Shen, Ying Zheng, Min Ruan, Zourong Biomed Res Int Clinical Study OBJECTIVE: This phase I study aimed to systematically assess the safety, local tolerability, pharmacokinetics, and preliminary efficacy of topical icotinib hydrochloride cream in patients with mild to moderate plaque psoriasis. MATERIALS AND METHODS: Eligible Chinese adult patients with mild to moderate psoriasis were assigned to the icotinib cream or vehicle group. Icotinib cream with increasing concentrations (0.5%, 1.0%, 2.0%, and 4.0%) or vehicle were administered by the fingertip unit method to the skin lesions twice a day for 4 weeks. Safety assessments included the incidence and severity of adverse events (AEs), local tolerability at the treatment area, vital signs, and laboratory examinations. Plasma levels of icotinib were also measured for the pharmacokinetics calculation. The efficacy was preliminarily explored by assessing the improvement in the severity level using Target Plaque Severity Score (TPSS) and overall improvement using the Psoriasis Area Severity Index (PASI) and Dermatological Quality Life Index. RESULTS: Forty-one patients were enrolled and qualified for safety analysis. 27 (65.9%) patients experienced at least one AE, of which application-site adverse drug reactions (ADRs) were reported in 6 (14.6%) patients. All ADRs were of grade 1 or 2, most common irritation (4.5%), itching (3.1%), and erythema (2.4%), and resolved during follow-up. The systemic exposure to icotinib was very low; the highest plasma concentration was 0.214 ng/mL, while the area under the curve from 0 to 12 hours was 1.626 h·ng/mL. The TPSS improved for all icotinib groups after treatment in a dose- and time-dependent manner. CONCLUSION: This phase 1 study demonstrated favorable safety, tolerable toxicity, and preliminary efficacy of icotinib cream in patients with mild to moderate psoriasis. The dose concentration of 2.0% (twice daily based on the fingertip unit method) is recommended for further study. STUDY DESIGN: This is a single-center, randomized, double-blind, and vehicle-controlled study. Hindawi 2019-05-02 /pmc/articles/PMC6521334/ /pubmed/31187048 http://dx.doi.org/10.1155/2019/9072683 Text en Copyright © 2019 Lunfei Liu et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Liu, Lunfei
Lou, Honggang
Zhou, Jiong
Shen, Ying
Zheng, Min
Ruan, Zourong
Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study
title Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study
title_full Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study
title_fullStr Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study
title_full_unstemmed Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study
title_short Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study
title_sort pharmacokinetics and safety of icotinib hydrochloride cream in patients with mild to moderate chronic plaque psoriasis: a randomized double-blind vehicle-controlled phase 1 study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521334/
https://www.ncbi.nlm.nih.gov/pubmed/31187048
http://dx.doi.org/10.1155/2019/9072683
work_keys_str_mv AT liulunfei pharmacokineticsandsafetyoficotinibhydrochloridecreaminpatientswithmildtomoderatechronicplaquepsoriasisarandomizeddoubleblindvehiclecontrolledphase1study
AT louhonggang pharmacokineticsandsafetyoficotinibhydrochloridecreaminpatientswithmildtomoderatechronicplaquepsoriasisarandomizeddoubleblindvehiclecontrolledphase1study
AT zhoujiong pharmacokineticsandsafetyoficotinibhydrochloridecreaminpatientswithmildtomoderatechronicplaquepsoriasisarandomizeddoubleblindvehiclecontrolledphase1study
AT shenying pharmacokineticsandsafetyoficotinibhydrochloridecreaminpatientswithmildtomoderatechronicplaquepsoriasisarandomizeddoubleblindvehiclecontrolledphase1study
AT zhengmin pharmacokineticsandsafetyoficotinibhydrochloridecreaminpatientswithmildtomoderatechronicplaquepsoriasisarandomizeddoubleblindvehiclecontrolledphase1study
AT ruanzourong pharmacokineticsandsafetyoficotinibhydrochloridecreaminpatientswithmildtomoderatechronicplaquepsoriasisarandomizeddoubleblindvehiclecontrolledphase1study